Halozyme Granted Another Injunction Against Merck in Keytruda Patent Case
Halozyme Therapeutics (HALO) won a patent case against Merck (MRK) in a Dutch court, which granted an injunction to halt the launch of Merck's Keytruda SC cancer treatment in several European markets. The court rejected Merck's arguments that the patent was invalid. Halozyme had previously sued Merck in Germany and the U.S.
How this was made
The 30-second read
Why it matters
The ruling blocks Merck's Keytruda SC launch, preserving Halozyme's patent rights and creating immediate legal and commercial ramifications for both firms.
Market read
First‑report legal development likely to move both stocks; investors should watch Merck's European launch timeline and Halozyme's licensing prospects.
What to watch
Potential for settlement or licensing deal that could offset revenue loss for Merck.
Background
A Dutch patent court found Merck infringing Halozyme's MDASE patent EP622 and issued an injunction covering eight European countries.
Ticker impact
Merck was ordered to stop selling Keytruda SC in several European countries, delaying its product launch.
likely downward pressure as investors price in lost sales and potential litigation costs.
First‑report legal setback directly affects Merck's European rollout and market perception.
Market effects
Biotech/pharma litigation risk perception may rise, affecting peers with similar patent exposure.
European markets for oncology drugs could see heightened volatility.
Limited to the two companies but may influence broader biotech M&A and licensing strategies.
Counterpoint
The injunction may be limited in scope and could be appealed, minimizing long‑term impact on Merck.
Key entities
- CompanyHalozyme Therapeutics
Biotech firm holding the MDASE patent.
- CompanyMerck & Co.
Pharmaceutical giant developing Keytruda SC.
